These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2720355)

  • 1. Plasma eicosanoids, platelet function and cold sensitivity.
    Wilkinson D; Vowden P; Gilks L; Latif AB; Rajah SM; Kester RC
    Br J Surg; 1989 Apr; 76(4):401-5. PubMed ID: 2720355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma 6 keto PGE1 alpha concentration in Raynaud's phenomenon.
    Kinney EL; Demers LM
    Prostaglandins Med; 1981 Nov; 7(5):389-93. PubMed ID: 6895673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An imbalance in plasma prostanoids in patients with Raynaud's phenomenon and pulmonary vasospasm.
    Sakamoto K; Houya I; Inoue K; Tanaka M; Suzuki T; Sakamoto Y; Matsuo H
    Eur Respir J; 1999 Jan; 13(1):137-44. PubMed ID: 10836338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal platelet aggregation in patients with Raynaud's phenomenon.
    Biondi ML; Marasini B
    J Clin Pathol; 1989 Jul; 42(7):716-8. PubMed ID: 2760232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoprostenol in patients with Raynaud's disease.
    Fitscha P; Kaliman J; Weidinger F; Sinzinger H; O'Grady J
    Prostaglandins Leukot Essent Fatty Acids; 1988 Jul; 33(1):23-7. PubMed ID: 3141936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of platelet function in patients with Raynaud's syndrome.
    Hutton RA; Mikhailidis DP; Bernstein RM; Jeremy JY; Hughes GR; Dandona P
    J Clin Pathol; 1984 Feb; 37(2):182-7. PubMed ID: 6229551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon.
    Luderer JR; Nicholas GG; Neumyer MM; Riley DL; Vary JE; Garcia G; Schneck DW
    Clin Pharmacol Ther; 1984 Jul; 36(1):105-15. PubMed ID: 6428793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet activation during hand vibration.
    Kent PJ; Williams GA; Kester RC
    Br J Surg; 1994 Jun; 81(6):815-8. PubMed ID: 8044590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon.
    Tindall H; Tooke JE; Menys VC; Martin MF; Davies JA
    Eur J Clin Invest; 1985 Feb; 15(1):20-3. PubMed ID: 3921380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.
    Herrick AL; Illingworth K; Blann A; Hay CR; Hollis S; Jayson MI
    Ann Rheum Dis; 1996 Feb; 55(2):122-7. PubMed ID: 8712862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of Raynaud's phenomenon in systemic scleroderma: comparative study with that in vibration disease].
    Maeda M; Shikano Y; Mori S
    Nihon Hifuka Gakkai Zasshi; 1989 Nov; 99(12):1255-9. PubMed ID: 2622060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet aggregation and evaluation of the ratio thromboxane B2/6-keto-prostaglandin F1 alpha in the plasma of patients on long term cimetidine treatment.
    Zavagli G; Taddeo U; Bolelli G; Orlandi M; Bartolini G; Tomasi V
    Prostaglandins Leukot Med; 1985 Sep; 19(3):241-50. PubMed ID: 2997804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W; Mastej K; Adamiec R
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma level and effects of thromboxane A2 and 6-keto-PGF1 alpha in patients with acute obstructive suppurative cholangitis].
    Miao XY
    Zhonghua Wai Ke Za Zhi; 1990 Apr; 28(4):228-30, 253-4. PubMed ID: 2379443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cold and emotional stress in Raynaud's disease and scleroderma.
    Freedman RR; Ianni P
    Br Med J (Clin Res Ed); 1983 Nov; 287(6404):1499-502. PubMed ID: 6416474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Platelet function study in primary Raynaud's phenomenon and Raynaud's phenomenon associated with scleroderma].
    Cuenca R; Fernández-Cortijo J; Lima J; Fonollosa V; Simeón CP; Pico M; Soriano B; Vilardell M
    Med Clin (Barc); 1990 Dec; 95(20):761-3. PubMed ID: 2151867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-adrenergic receptors in platelets from patients with Raynaud's syndrome.
    Keenan EJ; Porter JM
    Surgery; 1983 Aug; 94(2):204-9. PubMed ID: 6308842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.
    Reilly IA; Roy L; Fitzgerald GA
    Br Med J (Clin Res Ed); 1986 Apr; 292(6527):1037-9. PubMed ID: 3083991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of berberine on platelet aggregation and plasma levels of TXB2 and 6-keto-PGF1 alpha in rats with reversible middle cerebral artery occlusion].
    Wu JF; Liu TP
    Yao Xue Xue Bao; 1995; 30(2):98-102. PubMed ID: 7785438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.